| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/28/2002 | CA2419873A1 Process for preparation of anhydrous azithromycin |
| 02/28/2002 | CA2419840A1 Treatment of hyperproliferative diseases |
| 02/28/2002 | CA2419597A1 Solution composition of an oxazolidinone antibiotic drug having enhanced drug loading |
| 02/28/2002 | CA2419592A1 Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor |
| 02/28/2002 | CA2419580A1 Integrin receptor inhibitors |
| 02/28/2002 | CA2419310A1 Substituted piperidines as melanocortin receptor agonists |
| 02/28/2002 | CA2419266A1 4-, 5-, 6- and 7-indole derivatives useful for the treatment of cns disorders |
| 02/28/2002 | CA2418730A1 Oral fast-melt formulation of a cyclooxygenase-2 inhibitor |
| 02/28/2002 | CA2418464A1 Prophylactic or therapeutic agent for central nervous system diseases |
| 02/28/2002 | CA2418134A1 Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists |
| 02/28/2002 | CA2418104A1 Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists |
| 02/28/2002 | CA2417507A1 Novel thiourea derivatives and the pharmaceutical compositions containing the same |
| 02/28/2002 | CA2416748A1 Improved specificity in treatment of diseases |
| 02/28/2002 | CA2415852A1 Aminoalkoxybenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same |
| 02/28/2002 | CA2415846A1 Aminoalkenylbenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same |
| 02/28/2002 | CA2415838A1 Aza-amino acid derivatives (factor xa-inhibitors 15) |
| 02/28/2002 | CA2415793A1 Methods of drug delivery to hepatocytes and treatment of flaviviridae infections |
| 02/28/2002 | CA2415791A1 Treatment of wounds |
| 02/28/2002 | CA2415788A1 Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors |
| 02/28/2002 | CA2415349A1 Testosterone ester formulation for human use |
| 02/28/2002 | CA2415182A1 Pyrazole compounds, pharmaceutical compositions, and methods for modulating or inhibiting erab or hadh2 activity |
| 02/28/2002 | CA2411924A1 Heterocyclic-hydroxyimino-fluorenes and their use for inhibiting proteinkinases |
| 02/28/2002 | CA2356058A1 Intermittent administration of a growth hormone secretagogue |
| 02/28/2002 | CA2317305A1 Method of enhancing chondrocyte cell growth and glycosaminoglycan production |
| 02/27/2002 | EP1182459A2 Identifying material from a breast duct |
| 02/27/2002 | EP1182259A1 Pyruvate:NADP+ oxidoreductase and uses thereof |
| 02/27/2002 | EP1182256A1 Pollinosis-associated gene 513 |
| 02/27/2002 | EP1182208A2 Composition for DNA transfection |
| 02/27/2002 | EP1182206A2 Stabilized oligonucleotids and the use thereof |
| 02/27/2002 | EP1182204A1 Crystals of carbapenem derivatives and pharmaceutical preparations for injection |
| 02/27/2002 | EP1182202A1 Aminomethylpyrrolidine derivatives having aromatic substituents |
| 02/27/2002 | EP1182200A1 Tricyclic fused heterocycle compounds, process for preparing the same and use thereof |
| 02/27/2002 | EP1182195A1 Cyclic compounds and uses thereof |
| 02/27/2002 | EP1182194A1 Pernasal preparations |
| 02/27/2002 | EP1181954A2 Biphenyl-2-carboxylic acid-tetrahydro-isoquinolin-6-yl amide derivatives, their preparation and use as inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (ApoB) secretion |
| 02/27/2002 | EP1181943A1 Intravascular stents |
| 02/27/2002 | EP1181938A2 Rapamycin conjugates and antibodies |
| 02/27/2002 | EP1181937A2 Novel vaccine adjuvant and vaccine |
| 02/27/2002 | EP1181935A2 Agent for treating mental disorders associated with cerebrovascular disorders |
| 02/27/2002 | EP1181934A1 Inhibitors for optic hypofunction caused by optic nerve cell injury induced by factors other than optic circulatory disorder |
| 02/27/2002 | EP1181933A2 Use of growth hormone secretagogues for stimulating or increasing appetite |
| 02/27/2002 | EP1181932A2 Therapeutic compositions comprising excess enantiomer of amlodipine |
| 02/27/2002 | EP1181931A2 Intraoral adhesive preparation |
| 02/27/2002 | EP1181929A2 Method of potentiating an immune response and compositions therefor |
| 02/27/2002 | EP1181866A1 Antibacterial composition comprising Sandela |
| 02/27/2002 | EP1181555A1 Cancer treatment with endothelin receptor antagonists |
| 02/27/2002 | EP1181390A1 27 human secreted proteins |
| 02/27/2002 | EP1181376A2 Gene construct for prodrug activation encoding a heterologous, glycosylphophatidylinositol-modified carboxypeptidase g2 and a cell surface targeting signal peptide |
| 02/27/2002 | EP1181367A2 Polynucleotides and membrane-bound polypeptides encoded thereby |
| 02/27/2002 | EP1181329A1 Silicone gel containing salicylic acid |
| 02/27/2002 | EP1181320A2 Somatic transgene immunization and related methods |
| 02/27/2002 | EP1181316A1 DNA ENCODING SNORF36a AND SNORF36b RECEPTORS |
| 02/27/2002 | EP1181305A1 Methods of modulating activity of prokaryotic ribosomes |
| 02/27/2002 | EP1181304A1 Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin |
| 02/27/2002 | EP1181303A1 50 human secreted proteins |
| 02/27/2002 | EP1181302A1 Orally active a1 adenosine receptor agonists |
| 02/27/2002 | EP1181300A1 6-o-carbamate ketolide derivatives |
| 02/27/2002 | EP1181299A1 C-2 modified erythromycin derivatives |
| 02/27/2002 | EP1181298A1 Novel 8a- and 9a-15-membered lactams |
| 02/27/2002 | EP1181294A1 Novel derivatives and analogues of galanthamin |
| 02/27/2002 | EP1181292A1 Pyrozolo [3,4-d][1,2,3] triazines with an anticonvulsive action and methods for producing the same |
| 02/27/2002 | EP1181291A2 Dna methyltransferase inhibitors |
| 02/27/2002 | EP1181290A1 Polymorphs of a crystalline azabicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions |
| 02/27/2002 | EP1181289A1 Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2.2.2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-amine citrate as nk-1 receptor antagonists |
| 02/27/2002 | EP1181288A1 Bicyclic oxazolidinones as antibacterial agent |
| 02/27/2002 | EP1181287A1 Sulfonamide compounds with pharmaceutical activity |
| 02/27/2002 | EP1181286A1 3-(arylsulfonylamino)-tetrahydropyran-3-carboxylic acid hydroxamides |
| 02/27/2002 | EP1181285A2 3-(arylsulfonylamino)-tetrahydrofuran-3-carboxylic acid hydroxamides |
| 02/27/2002 | EP1181284A1 Diphenyl-1,2,3-thiadiazol-3-oxides, compositions and methods of use |
| 02/27/2002 | EP1181283A1 Diaminothiazoles and their use for inhibiting protein kinases |
| 02/27/2002 | EP1181282A2 Benzothiazinone and benzoxazinone compounds |
| 02/27/2002 | EP1181281A2 Novel carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their production and their use as endothelin receptor antagonists |
| 02/27/2002 | EP1181278A1 Cyclic amine derivatives and their uses |
| 02/27/2002 | EP1181276A1 Morpholino-n-ethyl ester derivative of an indole spla-2 inhibitor |
| 02/27/2002 | EP1181275A1 Thio-oxindole derivatives |
| 02/27/2002 | EP1181274A1 Iminocyclitol inhibitors of hexoaminidase and glycosidase |
| 02/27/2002 | EP1181271A2 Naphthalene ureas as glucose uptake enhancers |
| 02/27/2002 | EP1181270A2 Inhibitors of factor xa |
| 02/27/2002 | EP1181269A1 Cell proliferation inhibitors |
| 02/27/2002 | EP1181266A1 Squaric acid derivatives as cell adhesion molecules |
| 02/27/2002 | EP1181190A1 Method and apparatus for loading a container with a product |
| 02/27/2002 | EP1181055A2 Enzyme-activated anti-tumor prodrug compounds |
| 02/27/2002 | EP1181048A1 A pharmaceutical formulation containing an inhibitor of carboxypeptidase u and a thrombin inhibitor |
| 02/27/2002 | EP1181042A1 Neurotrophic factors in the treatment of peripheral nerve dysfunction of pelvic area |
| 02/27/2002 | EP1181037A2 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 02/27/2002 | EP1181034A2 Combinations of immunosuppressive agents for the treatment or prevention of graft rejections |
| 02/27/2002 | EP1181031A1 Novel antiangiogenic peptides |
| 02/27/2002 | EP1181027A2 Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria |
| 02/27/2002 | EP1181024A1 Glycosaminoglycans having an average molecular weight equal to 2400 d suitable for the treatment of senile dementia |
| 02/27/2002 | EP1181023A1 Compositions of polyacids and polyethers and methods for their use in reducing adhesions |
| 02/27/2002 | EP1181022A1 Medicinal compositions and their method of preparation |
| 02/27/2002 | EP1181021A1 Novel, specific inhibitors of acute and chronic inflammation |
| 02/27/2002 | EP1181020A2 Vitamin d derivatives for the teatment of systemic lupus erythematosus |
| 02/27/2002 | EP1181019A1 Use of adenosine deaminase inhibitors to treat systemic inflammatory response syndrome |
| 02/27/2002 | EP1181018A1 Ziprasidone suspension |
| 02/27/2002 | EP1181017A1 Metalloprotease inhibitors |
| 02/27/2002 | EP1181016A1 Chemical compounds having ion channel blocking activity for the treatment ofimmune dysfunction |
| 02/27/2002 | EP1181015A2 Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron |
| 02/27/2002 | EP1181014A1 HETEROCYCLIC CONTAINING BIPHENYL aP2 INHIBITORS AND METHOD |
| 02/27/2002 | EP1181013A1 Method and composition for the treatment of cancer |